C07J 41/00
Normal steroids containing one or more nitrogen atoms not belonging to a
Official title: Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
C07J41/00 (Normal steroids containing one or more nitrogen atoms not belonging to a) appears on 1,585 US grants and 1,181 published applications in this corpus.
Search patents in C07J- Granted patents
- 1,585
- Published applications
- 1,181
- Assignees
- 691
- Inventors
- 3,106
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 33 | 0 |
| 1977 | 27 | 0 |
| 1978 | 32 | 0 |
| 1979 | 21 | 0 |
| 1980 | 38 | 0 |
| 1981 | 26 | 0 |
| 1982 | 23 | 0 |
| 1983 | 18 | 0 |
| 1984 | 29 | 0 |
| 1985 | 24 | 0 |
| 1986 | 28 | 0 |
| 1987 | 21 | 0 |
| 1988 | 14 | 0 |
| 1989 | 24 | 0 |
| 1990 | 35 | 0 |
| 1991 | 25 | 0 |
| 1992 | 31 | 0 |
| 1993 | 32 | 0 |
| 1994 | 28 | 0 |
| 1995 | 37 | 0 |
| 1996 | 47 | 0 |
| 1997 | 62 | 0 |
| 1998 | 61 | 0 |
| 1999 | 58 | 0 |
| 2000 | 43 | 0 |
| 2001 | 34 | 7 |
| 2002 | 40 | 47 |
| 2003 | 28 | 50 |
| 2004 | 26 | 40 |
| 2005 | 20 | 45 |
| 2006 | 26 | 31 |
| 2007 | 17 | 25 |
| 2008 | 13 | 21 |
| 2009 | 17 | 29 |
| 2010 | 25 | 43 |
| 2011 | 16 | 32 |
| 2012 | 14 | 45 |
| 2013 | 25 | 36 |
| 2014 | 23 | 50 |
| 2015 | 33 | 51 |
| 2016 | 30 | 72 |
| 2017 | 48 | 65 |
| 2018 | 37 | 54 |
| 2019 | 64 | 65 |
| 2020 | 50 | 62 |
| 2021 | 42 | 66 |
| 2022 | 36 | 58 |
| 2023 | 31 | 57 |
| 2024 | 27 | 46 |
| 2025 | 33 | 43 |
| 2026 | 13 | 41 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof6 Oct 2026US 12,753,204 B2Enanta Pharmaceuticals, Inc.
- Orally active leukemia inhibitory factor (LIF) antagonists for the treatment of cancer29 Sep 2026US 12,747,263 B2Evestra, Inc.
- Crystal form of 3-hydroxy-5-pregnane-20-one derivative, and preparation method therefor and use thereof15 Sep 2026US 12,735,448 B2TWi Biotechnology, Inc.
- Bile acid-GCPII inhibitor conjugates to treat inflammatory diseases, including inflammatory bowel disease (IBD)4 Aug 2026US 12,698,306 B2Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
- Crystalline forms of squalamine21 Jul 2026US 12,686,699 B2Enterin, Inc.
- Spleen-targeted lipid nanoparticles1 Oct 2026US 2026/0294826 A1Beijing Jitai Pharmaceutical Technology Co., Ltd.
- Neurosteroids and Prodrugs Thereof24 Sep 2026US 2026/0285897 A1Emory University
- Salt form and polycrystalline form of allopregnanolone derivative, preparation method therefor, and use thereof17 Sep 2026US 2026/0274887 A1Nanjing Minova Pharmaceutical Co., Ltd.
- Aminosterol compounds, aminosterol-cyclodextrin formulations, and methods of using the same10 Sep 2026US 2026/0263485 A1Enterin, Inc.
- 3-alpha substituted 3-beta-hydroxy-17-oximated androstane compound for modulation of the alpha-3 subtype of the gabaa receptor10 Sep 2026US 2026/0265290 A1Umecrine Cognition AB
Most cited
By later US patents
- Method for delivering nucleic acids into cells278US 5,283,185 AMcMaster University · 1994
- Oligonucleotide having enhanced binding affinity276US 5,486,603 AGilead Sciences, Inc. · 1996
- Label modified immunoassays229US 4,208,479 ASyva Company · 1980
- Conjugates and compositions for cellular delivery194US 7,491,805 B2Sirna Therapeutics, Inc. · 2009
- 4-Aza-17.beta.-substituted-5.alpha.-androstan-3-one-reductase inhibitors159US 4,377,584 AMerck & Co., Inc. · 1983